BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances Kilogram-Scale Manufacturing for ONC010 Program 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. 

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in the development of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. Conducted through its chemistry, manufacturing and controls collaboration with Dalton Pharma Services, the effort resulted in the production and isolation of approximately 952 grams of B4 material, supporting future formulation development, GMP production and planned clinical studies.

The company said the manufacturing milestone strengthens its integrated development strategy and supports the establishment of a scalable production process for future clinical supply. Onco-Innovations also announced the engagement of InvestorBrandNetwork (“IBN”) to provide market awareness, corporate communications and digital media services through Sept. 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 for the services and intends to apply an unused US$80,000 balance returned from a prior market awareness engagement toward the consideration.

To view the full press release, visit https://ibn.fm/BbWHd

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.

For more information go to https://oncoinnovations.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN